Menin inhibitors in AML: Bridging the gap between trial data and clinical practice

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/ac/db/b3/acdbb369-23a5-f4ef-1717-3b6405d74b6f/mza_5928252466954251512.jpeg/600x600bb.jpg

AML Hub

Scientific Education Support

29 episodes

3 weeks ago

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Education

RSS

All content for AML Hub is the property of Scientific Education Support and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Hosted on Acast. See acast.com/privacy for more information.

Education

https://assets.pippa.io/shows/undefined/1585645708468-f1820b05797bc1563ae18cf50ab2ecce.jpeg

Menin inhibitors in AML: Bridging the gap between trial data and clinical practice

AML Hub

7 minutes 1 second

1 month ago

Menin inhibitors in AML: Bridging the gap between trial data and clinical practice

The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial data and clinical practice.”

Searle summarizes the key considerations when using menin inhibitors in the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) in clinical practice, and her thoughts on key areas of interest looking forward.

This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.